Please refer attachment
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Emmessar Biotech & Nutrition Ltd submitted its unaudited financial results for Q2 FY26 and the half year ended September 30, 2025, which were reviewed by V. Nagarajan & Co. and approved by the Board on November 12, 2025. Total income for Q2 FY26 came in at Rs 125.74 lakhs, sharply lower than Rs 261.96 lakhs in Q2 FY25 (a roughly 50% drop year-on-year). For the half year, the company swung from a small profit of Rs 27.85 lakhs in H1 FY25 to a loss before tax of about Rs (64.21) lakhs in H1 FY26. The auditor's limited review report is clean, with no qualifications or emphasis-of-matter issues raised.
This is a negative result for shareholders — revenue has halved compared to the same quarter last year and the company has slipped from profit into loss. Expect weak sentiment on the stock unless management provides a clear turnaround plan.